Phio Pharmaceuticals (PHIO) Q3 2025 earnings summary

Executive summary

• Advanced INTASYL® RNAi technology for immuno-oncology, with PH-762 in Phase 1b clinical trials for skin cancers, reaching the fifth and final cohort at maximum dose and showing strong tumor clearance responses with no dose-limiting toxicities.

• Cost rationalization in 2024 included headcount reduction and transition to remote operations, redirecting resources to clinical development.

• Terminated AgonOx collaboration in May 2024, settling all obligations and focusing on internal programs.

• Cash runway extended into the first half of 2027 following recent warrant inducement financings.

Financial highlights

• Net loss for Q3 2025 was $2.4 million, compared to $1.5 million in Q3 2024; net loss for the nine months ended September 30, 2025 was $6.3 million, up from $5.5 million year-over-year.

• Operating expenses increased to $2.5 million in Q3 2025 (up 58% year-over-year), driven by higher R&D and G&A costs.

• Cash and cash equivalents were $10.7 million as of September 30, 2025, up from $5.4 million at December 31, 2024; estimated cash and cash equivalents as of the release date were $21.3 million.

• Net cash used in operating activities for the nine months ended September 30, 2025 was $5.9 million; net cash provided by financing activities was $11.2 million.

• Research and development expenses rose to $1.2 million from $0.6 million year-over-year; G&A expenses increased to $1.3 million from $0.9 million.

Outlook and guidance

• Projected cash position is expected to sustain operations into the first half of 2027, supported by $13.4 million gross proceeds from a November 2025 financing.

• Continued negative cash flows and operating losses expected as clinical development progresses.

• Plans to continue screening and treating additional patients in the fifth cohort of the PH-762 trial.

• Future funding needs will depend on clinical trial progress, pipeline expansion, and market conditions.